Abstract: A device for use with a bed having a frame and a supporting surface includes a flexible sheet with a tether strap connected to the sheet and extending from the sheet. The flexible sheet has opposed top and bottom surfaces, with the top surface having a high friction material with a higher coefficient of friction as compared to the bottom surface, which includes a low friction material. The tether strap is configured for connection to the frame of the bed to secure the sheet in place. A system incorporating the flexible sheet may also include an absorbent pad configured to be placed on the top surface of the sheet, where the high-friction top surface resists sliding of the absorbent pad, as well as one or more wedges having a base wall that the wedge rests on and a ramp surface configured to confront the sheet when the wedge is placed under the sheet. The base wall and the ramp surface may also contain high friction and low friction materials, respectively.

Abstract: A patient support for supporting a patient includes an inflatable mattress defining a support surface and a pneumatic system for inflating the inflatable mattress. The pneumatic system includes a pressurized reservoir for holding pressurized air and selectively releases pressurized air from the reservoir to the mattress.

Abstract: The present invention includes a bed sheet having one or more features to accommodate a user's grasp whereby to assist the user in safely lifting a patient with the bed sheet. The invention further includes a hoist system configured to raise and lower the bed sheet via the one or more features to accommodate a user's grasp. The one or more grasping features of the bed sheet may include handles that are secured to the bed sheet using an integrated webbing that allows the bed sheet to be used to transport patients from one location to another, such as from a gurney to a hospital bed. An integrated webbing of the bed sheet strengthens an interface between handles and a top portion of the bed sheet so that patients of substantial weight can be transported via the bed sheet.

Abstract: A heat therapy device including a care unit presenting a lying surface for supporting an infant, a hood which is moveable between a closed position covering the care unit and an opened position clearing the top of the care unit, a radiation heater arranged to irradiate the lying surface in the opened position of the hood, a convection heater, and control units which are configured and arranged to control the operation of the radiation and convection heaters, wherein the control units are configured and arranged to control the operation of the convection heater as a primary heater when the hood is in the closed position and to control the operation of the radiation heater as the primary heater when the hood is in the opened position.

Abstract: A multipurpose infant positioning device that includes a lower pad with front and back surfaces, wings attached to lateral sides of the lower pad and a bottom flap attached to the bottom portion of the lower pad. At least one of the wings and bottom flap have fastening segments attached thereto for adjustably attaching these components to portions of the lower pad. The fastened wing and bottom flap are made of a material having sufficient resiliency to maintain and bring an infant back to flexed midline position within the infant positioning device. These infant positioning devices may further include a headpiece, brim, pocket at the back surface of the lower pad and a detachable readjustable multipurpose pillow for positioning the infant from and between supine, prone and side-lying positions, all while maintaining and reinforcing the flexed midline position of the infant for normal development.

Abstract: A method and apparatus for rehabilitation and training of an injured limb by using the corresponding functional healthy limb to control the motion of the injured limb are presented. A sensor system on the healthy and active limb, a processing unit, and a power supply are provided in the apparatus to provide signals that activate a powered mechanism configured for moving individual bones on the injured passive limb.

Abstract: An apparatus, system and method are disclosed for manipulating a user's erogenous zone. The apparatus includes a chamber, a plurality of baffling elements, and a concentration member. The chamber has a first end opposing a second end. The first end of the chamber is communicable in water receiving communication with a water source. The plurality of baffling elements are positioned within the chamber and are configured to interrupt a flow of water received from the first end of the chamber. The concentration member defines a channel having a water receiving end and a water dispensing end. The channel has a converging cross-sectional area in a direction from the water receiving end to the water dispensing end with the water receiving end communicable in water receiving communication with water flowing past the baffling elements.

Abstract: A biological measurement apparatus of this invention includes (i) a micro piezoelectric element for vibrating a nerve cell of a subject without coming in contact with the nerve cell, (ii) an electromagnetic wave antenna for receiving an electromagnetic wave generated by the nerve cell vibrated by the micro piezoelectric element, and (iii) a computer for measuring an electric charge of the nerve cell based on the electromagnetic wave received by the electromagnetic wave antenna. Further, this biological measurement apparatus includes an electromagnetic wave antenna for emitting an electromagnetic wave to a nerve cell. This configuration provides an apparatus capable of measuring an electrical activity of a nerve cell in a living organism in real time and three-dimensionally at a spatial resolution of a nerve cell size. Moreover, this configuration provides an apparatus capable of individually giving electrical stimulations to any desired cells in the subject.

Abstract: A device (100) for the treatment of depression, anxiety and pain, the device comprising: a plurality of adjacent dots (11) or other shapes, each comprising means for providing a signal being sensible by a touch sense, the signal comprising mechanical signal and/or electrical signal and/or temperature signal and/or magnetic signal; and a controller (32) for executing each of the means independently, for providing pre-programmed shapes (30, 40, 40A, 40B, 42, 46, 48, 50, 52, 54) being sensible by the touch sense, thereby allowing treating the depression, anxiety and pain by generating to the brain, signals resembling the pre-programmed shapes (30, 40, 40A, 40B, 42, 46, 48, 50, 52, 54) through the signals being sensible by the touch sense.

Abstract: A blood bag system (10) includes a blood bag (14) to which centrifugal force is provided in a state where whole blood or a blood component is stored, and a first tube (22) that circulates a fluid centrifugally separated from the blood bag (14). The first tube (22) includes an extending portion (112) extending in an approximately perpendicular direction to a centrifugal direction into which the centrifugal force is applied. Further, a branch tube (114) that can store blood existing in the extending portion (112) is provided at a side of the centrifugal direction of the extending portion (112).

Abstract: A cartridge for use with a beneficial agent delivery device having a fillable reservoir. The cartridge includes a reconstitution, unit dose package having first and second compartments, and a fitment. The first compartment contains at least a first constintuent of the beneficial agent. The second compartment contains at least a second constituent of the beneficial agent. The fitment is disposed on the package for interfacing the package to the fillable reservoir.

Abstract: There is disclosed a drinking receptacle comprising: a container for containing a fluid for drinking; and an outlet member having an outlet through which the fluid is delivered under a pressure supplied by a user of the receptacle and a collar portion that attaches to an opening of the container such that an undersurface of the collar portion abuts with an upper surface of the opening of the container to form a substantially sealed engagement between the outlet member and the container; wherein either the undersurface of the collar portion or the upper surface of the opening of the container has at least one vent formed therein, the at least one vent being configured such that when said pressure is applied to the outlet member the at least one vent member permits the controlled ingress of air into the container to facilitate flow of fluid from the outlet, and when said pressure is removed the at least one vent member substantially prevents the ingress of air into the container to facilitate a controlled vacuu

Abstract: A naso/orogastric device that comprises a naso/orogastric tube sized and shaped for being disposed within the esophagus so that at least a distal segment thereof being placed in the stomach lumen of a patient and at least one self expending element disposed around a peripheral surface of the naso/orogastric tube and having a first thickness in a compressed state and a second thickness in an expanded state, the at least one self expending element switching from the compressed state to the expanded state when absorbing moisture. The first thickness is thinner than the second thickness.

Abstract: A flow control apparatus adapted to receive a feeding set includes a housing capable of receiving at least a portion of the feeding set. A pumping device is supported by the housing and positioned to contact the feeding set when the feeding set is received by the housing so the pumping device acts on the feeding set to produce fluid flow in the feeding set for delivery of fluid to a subject. An ultrasonic sensor is supported by the housing and arranged with respect to the pumping device to produce a sensor signal indicative of a viscosity of the fluid delivered through the feeding set. A control circuit is in communication with the ultrasonic sensor for receiving the sensor signal from the sensor indicative of the viscosity of the fluid and in communication with the pumping device to control operation thereof.

Abstract: Provided are metal oxide ceramic materials and intermediate materials thereof (e.g., nanozirconia gels, nanozirconia green bodies, pre-sintered ceramic bodies, zirconia dental ceramic materials, and dental articles). The nanozirconia gels are formable gels. Also provided are methods of making and using the metal oxide materials and intermediate materials. The nanozirconia gels can be made using, for example, osmotic processing. The nanozirconia gels can be used to make nanozirconia green bodies, pre-sintered ceramic bodies, zirconia dental ceramic materials, and dental article. The nanozirconia green bodies, pre-sintered ceramic bodies, zirconia dental ceramic materials, and dental articles have desirable properties (e.g., optical properties and mechanical properties).

Abstract: The present invention provides a delivery system for the treatment and/or prevention of infectious pathological changes, including compositions comprising polyhexanide, various pharmaceutical formulations, and processes for using these formulations in oral treatment modalities.

Abstract: The invention comprises an emulsifier-free, skin-conditioning, cosmetic or dermatological preparation having a granular structure, characterized by contents of fatty alcohols and wax or paraffin for use on wet skin. The preparation is characterized by a special production method, which in turn only brings about the advantageous properties of a skin conditioning.

Abstract: The present invention relates to a sunscreen composition comprising: a. an aqueous phase; b. an oil phase comprising at least one cosmetically acceptable oil; c. at least one sunscreen active; and d. up to about 5% by weight, based on the total weight of the composition, of an emulsifier system comprising; i. at least one ionic surfactant; ii. at least one nonionic surfactant having an HLB of greater than or equal to about 14; and iii. at least one nonionic surfactant having an HLB of less than or equal to about 10; wherein the composition is an oil-in-water emulsion containing oil droplets having an average particle size of from about 100 to 150 nm, is alcohol-free, and appears semi-transparent to transparent upon application onto an end-user's skin.

Abstract: The present disclosure relates to methods for improving the quality and durability of color in artificially colored hair. The methods employ alkaline earth metal salts that act as a mordant (a fixing agent) with the dye and hydroxy-polycarboxylic acids, which act as chelators. The artificially colored hair is treated with a post-color treatment composition comprising one or more alkaline earth metal salts and one or more hydroxy-polycarboxylic acids. Also, the one or more alkaline earth metal salts may be incorporated into a coloring composition for coloring the hair (in-color treatment composition) and a subsequent post-color treatment composition comprising one or more hydroxy-polycarboxylic acids can be applied to the hair.

Abstract: The invention relates generally to new compounds of formula (I), wherein R1, R?1, R2, R?2, R3, R?3, R4 R?4, R5, R?5, R6, R7 are independently of one another and denote hydrogen, hydroxyl, C1 to C6-alkyl group or R6 and R7 form together a C5-C6 ring system, and wherein n=0, 1, 2, 3, or 4. Moreover, the invention relates to the use of one or more compounds of formula (I) in cosmetic or pharmaceutical compositions, which are preferably dermatological compositions and are preferably used topically.

Abstract: The disclosure provides a liquid hand soap or body wash, comprising (i) a surfactant system comprising C8-18 alkyl-ether sulfate, cocamidopropyl betaine (CAPB), and N-(2 hydroxyethyl) fatty acid amide; (ii) a polyethylene oxide-polypropylene oxide block copolymer; and (iii) one or more polyalkoxylated mono- or di-fatty acid esters or amides, the composition allowing reduced surfactant levels, while still having good rheological properties.

Abstract: The present invention provides a skin cosmetic containing the following components (A), (B), (C), (D), (E), and (F): (A) 0.5 to 7 mass % of a linear saturated fatty acid having 12 to 22 of carbon atom, (B) 0.01 to 5 mass % of an organic base, (C) 0.01 to 1 mass % of an inorganic base, (D) 0.6 to 7 mass % of a linear saturated alcohol having 12 to 22 of carbon atom, (E) 0.1 to 20 mass % of an oil agent, and (F) water, wherein the total amount of the components (A) and (D) is (A)+(D)=from 1 to 14 mass %, the mass ratio of the component (A) to the total amount of the components (A) and (D) [(A)+(D)] is (A)/[(A)+(D)]=from 0.1 to 0.9, the molar ratio of the component (B) to the total amount of the components (B) and (C) [(B)+(C)] is (B)/[(B)+(C)]=from 5 to 50 mol %, and the molar ratio of the total amount of the components (B) and (C) [(B)+(C)] to the component (A) is [(B)+(C)]/(A)=more than 80 mol % and 120 mol % or less.

Abstract: The present invention relates to a cosmetic composition, comprising: (a) at least one compound having a specific chemical structure with two or more fatty amide groups; (b) at least one monosacharide. The cosmetic composition according to the present invention can have superior skin hydration effects because the hydration effect of each of the components (a) and (b) is synergistically enhanced by the combination of the components (a) and (b).

Abstract: Disclosed are clear, aqueous perfume compositions which are free of ethanol. There is further provided a perfume composition which is clear, provides a good skin feeling, and good air drying properties on the skin.

Abstract: Cationic and silicon substituents are introduced into polysaccharides thereby producing modified polysaccharides cationically substituted by quaternary ammonium groups and having a charge density of about 0.1 to about 2.5 meq/g, and further substituted by siliconate groups such that the modified polysaccharide has a silicon content of about 300 to about 5000 ppm. The modified polysaccharides have application in industrial, home care and personal care surface modifying formulations.

Abstract: Described are personal care compositions comprising a polymer comprising: (a) one or more polymer comprising, as polymerized units, (i) 75% to 35% by weight, based on the weight of said polymer, one or more (meth)acrylate monomer selected from at least one of C1-C4 (meth)acrylate, (meth)acrylic acid, styrene, or substituted styrene, and (ii) 25% to 65% by weight, based on the weight of said polymer, one or more hydrophobic monomer, including hydrophobically substituted (meth)acrylate monomers, with alkyl chain length from C8 to C22 and, (iii) optionally crosslinker, and, (b) at least one personal care active. Optionally, the polymer further includes a stage 2 polymer comprising, as polymerized units, (i) 10-99% of one or more monomer which has a Tg of more than 80° C. after polymer formation, (ii) 1-10% of one or more (meth)acrylate monomer containing acid functional group, and (iii) optionally, a crosslinker.

Abstract: The invention describes aqueous, surfactant-containing and/or transparent cleansing preparations containing novel associative thickeners, the A-MA polymers. Solid particles, bubbles and/or droplets can be present as a stable suspension in the preparations.

Abstract: Provided are nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one acrylic non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition.

Abstract: The present invention relates to cosmetics comprising a hydroxyl compound obtained by the reaction of a di- or higher-valent alcohol with a monovalent carboxylic acid and dimer acid, characterized in that the hydroxyl compound is obtained by reacting diglycerin with isostearic acid, and then reacting the obtained ester compound with dimer acid, wherein a molar ratio among diglycerin, isostearic acid and dimer acid is in the range of 1.0:1.4 to 1.6:0.5 to 0.8. The present invention provides cosmetics comprising the hydroxyl compounds having a high hydroxyl value.

Abstract: The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (NSCs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth. Thus, it is useful for hair growth stimulation and hair loss prevention.

Abstract: The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.

Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

Abstract: The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analog can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine.

Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Abstract: The present invention provides a composition and an antiviral drug preparation, each comprising at least one water-insoluble antiviral drug and at least one water-soluble carrier material, wherein the water-insoluble antiviral drug is dispersed through the water-soluble carrier material in nano-disperse form. The present invention further provides processes for preparing the compositions and drug preparations, and also aqueous nano-dispersions obtained by combining water and the compositions.

Abstract: The present invention provides novel liposomal formulations of polymyxin B and pharmaceutical compositions thereof useful for the treatment of bacterial infections. The liposomal formulation comprises a lipid component formed as vesicles each having a minimum size of at least 500 nm and polymyxin B encapsulated in the vesicles. The present invention also provides a drug delivery system that comprises a plurality of liposomes encapsulating a polymyxin B therein, where the liposomes have a minimum vesicular size of at least 500 nm. The liposomes comprising the drug delivery system are useful to increase efficacy of a treatment for a bacterial infection by increasing bioavailability and distribution of the polymyxin B within the subject.

Abstract: The present invention provides a composition comprising a sPLA2 hydrolysable liposome, an exterior solution, and an interior solution within the liposome, —wherein the concentration of osmolytes is higher in the interior solution than in the exterior solution. The composition improves storage stability of sPLA2 hydrolysable liposomes, in particular at when stored at 2-8 degrees Celsius. The liposome preferably encapsulates cisplatin. The invention also provides methods of preparing the composition of the invention.

Abstract: The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.

Abstract: The present invention relates to amoxicillin trihydrate compositions having a surface area of from 1.0 to 2.5 m2·g?1 that are free of organic contaminants such as dichloromethane, isopropanol, pivalic acid and triethyl amine and that have a purity of from 97.0% to 99.99%. Furthermore, the present invention relates to a method for the preparation of said amoxicillin trihydrate compositions and to the use of said compositions for the treatment of a bacterial infection.

Abstract: Methods of making and resultant acidulent/carbohydrate agglomerates. The acidulent may be citric acid having particle sizes ranging from about 1 micron to 20 microns agglomerated with a soluble carbohydrate co-agglomerate to formulate the various acidulent/carbohydrate agglomerates. In certain embodiments, the carbohydrate co-agglomerate may be maltodextrin to formulate citric acid/maltodextrin agglomerates. These citric acid/maltodextrin agglomerates are shelf stable when dry, have improved flowability, compressibility, mixability; dissolve easily and quickly in water; and provide an easy ready-to-use formulation that is suitable for use in compounding various food and pharmaceutical products.

Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.

Abstract: An object is to provide a method of manufacturing a seamless soft capsule that is enteric and excellent in formulation properties. An enteric seamless soft capsule is manufactured by the following steps (a) and (b): (a) preparing an enteric capsule shell liquid comprising gelatin and low methoxy pectin having a degree of esterification of 0 to 40% and a degree of amidation of 0 to 25%, the enteric capsule shell liquid having a viscosity at 50° C. of 60 to 127 mPa·s; and (b) encapsulating capsule fills with the enteric capsule shell liquid prepared in the step (a) by dripping. Preferably, the jelly strength of the gelatin is 180 to 330 Bloom, an aqueous solution of the low methoxy pectin at a concentration of 2 mass % has a viscosity at 35° C. of 8 to 15 mPa·s, and the enteric capsule shell liquid comprises 10 to 20 parts by mass of the low methoxy pectin per 100 parts by mass of gelatin.

Abstract: The present invention concerns a new composition based on pellets of lipoic acid in a lipophilic medium, if necessary combined with other active ingredients.

Abstract: The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.

Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.

Abstract: Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.

Abstract: The present invention is directed methods of lowering intraocular pressure in a patient suffering from elevated intraocular pressure or glaucoma and treating ocular disease by administering a drug to the periorbital skin of the patient.